Provided by Tiger Fintech (Singapore) Pte. Ltd.

Johnson & Johnson

168.78
+2.091.25%
Volume:6.47M
Turnover:1.09B
Market Cap:406.35B
PE:29.15
High:169.90
Open:167.31
Low:167.05
Close:166.69
Loading ...

Johnson & Johnson's Investigational Colitis Treatment Meets Primary Endpoint in Phase 2b Trial

MT Newswires Live
·
Yesterday

Health Canada Authorizes Lazcluze® (Lazertinib) in Combination With Rybrevant® (Amivantamab) as a First-Line Chemotherapy-Free Treatment for Patients With Egfr-Mutated Advanced Lung Cancer

THOMSON REUTERS
·
Yesterday

Health Canada authorizes LAZCLUZE® (lazertinib) in combination with RYBREVANT® (amivantamab) as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer

CNW Group
·
Yesterday

Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis

ACCESS Newswire
·
Yesterday

Icotrokinra Meets Primary Endpoint of Clinical Response in Ulcerative Colitis Study and Shows Potential to Transform the Treatment Paradigm for Patients

THOMSON REUTERS
·
Yesterday

J&J: Icotrokinra Was Well Tolerated

THOMSON REUTERS
·
Yesterday

Icotrokinra meets primary endpoint of clinical response in ulcerative colitis study and shows potential to transform the treatment paradigm for patients

PR Newswire
·
Yesterday

Take the Zacks Approach to Beat the Markets: NioCorp, AngloGold, Amgen in Focus

Zacks
·
Yesterday

3 ETFs to Buy Now for Passive Dividend Income

Motley Fool
·
09 Mar

BRIEF-J&J Says Phase 3 Iconic-Advance 1&2 Studies Met Their Co-Primary Endpoints

Reuters
·
08 Mar

J&J - Icotrokinra Results Show Potential to Set a New Standard of Treatment in Plaque Psoriasis

THOMSON REUTERS
·
08 Mar

J&J - Phase 3 Iconic-Advance 1&2(E )Studies Met Their Co-Primary Endpoints

THOMSON REUTERS
·
08 Mar

Icotrokinra results show potential to set a new standard of treatment in plaque psoriasis

PR Newswire
·
08 Mar

Buy Gilead Sciences (GILD) Stock at 52-Week Highs?

Zacks
·
08 Mar

Pfizer Appoints Ex-J&J Leader to Accelerate Weight Loss Solutions

GuruFocus.com
·
08 Mar

JNJ Halts Development of Depression Drug Over Efficacy Concerns

Zacks
·
08 Mar